Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAD106 with or without adjuvant in mild Alzheimer's disease
NL-OMON36379Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2010
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of amilomotide in Alzheimer's disease (AD) (9 cohorts), sponsored by Novartis. Primary endpoints: Frequency of adverse events, Cerebral MRI scan safety assessments and 10 more. Started Jun 2010; status: active, not recruiting.
02
Drugs
amilomotide
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON36379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36379.